The gastrointestinal effects of the GLP-1 class come mainly from slowed gastric emptying. Among GLP-1 side effects, nausea is the one reported most often. In the trials these effects are dose-dependent, mostly mild to moderate, concentrated during the escalation phase, and they ease once maintenance is reached.
The mechanism: gastric emptying and vagal signaling
GLP-1 does not act on the pancreas alone. Two of its effects account for almost everything that happens in the digestive tract:
It slows gastric emptying. The stomach takes longer to pass its contents into the intestine. That is, in large part, the reason for prolonged satiety, and also the reason gastric contents sit longer where they can trigger nausea or reflux.
It acts on the area postrema. This is the brainstem region that controls vomiting, and it sits outside the blood-brain barrier, which means it is exposed to whatever circulates in the blood. It carries GLP-1 receptors. Activating it is the direct route to nausea, independent of anything happening in the stomach.
That these are two separate mechanisms matters. It explains why nausea can appear with no sense of fullness at all, and why the effects do not follow one shared time course.
Nausea: why it appears and why it fades
Nausea is the most frequent adverse event in the class, and its pattern is easy to recognize: it appears after a dose increase, peaks over the following days, and declines if the dose is held steady.
What sits behind that is receptor adaptation. Sustained exposure reduces the response to the same signal, a general phenomenon in receptor pharmacology, and the body comes to tolerate a concentration that was too much at the start.
That is exactly why the trials escalate the dose in stages instead of starting at the top. The design is not bureaucratic caution; it is how that adaptation gets put to work. The article on titration goes into it.
Constipation: the effect that lasts longest
Constipation follows a different and less favorable course. Where nausea usually softens, constipation tends to persist for as long as exposure continues.
It makes mechanistic sense. Constipation does not depend on the sensitivity of the area postrema but on slowed transit, which is a sustained effect. On top of that, lower intake (a consequence of satiety) cuts volume, fiber, and fluids, and that worsens the picture by an independent route.
In TRIUMPH-1, at the highest dose, constipation was reported in 26.1% of participants.
Reflux and the case of prior surgery
Slowed emptying raises the likelihood of gastroesophageal reflux, above all in people who already had it.
One situation deserves explicit mention: people with prior gastrointestinal surgery, bariatric or otherwise, have altered anatomy and motility, and they are not represented in most trials of the class. What is known about the general study population does not carry over to that group, and that is a medical consultation, not a data point an article can settle.
Discontinuation rates by dose in the trials
Here it helps to look at the full numbers, not only the efficacy percentages.
TRIUMPH-1 (retatrutide, 80 weeks, preliminary communication from May 2026), at the highest dose:
| Event | Reported rate |
|---|---|
| Nausea | 42.4% |
| Diarrhea | 32.0% |
| Constipation | 26.1% |
| Vomiting | 25.3% |
| Dysesthesia and urinary tract infections | ~10% |
Discontinuations due to adverse effects, by group:
| Group | Discontinuation |
|---|---|
| Placebo | 4.9% |
| Retatrutide 4 mg | 4.1% |
| Retatrutide 9 mg | 6.9% |
| Retatrutide 12 mg | 11.3% |
The staircase is clear: more dose, more dropout. One in nine participants on the high dose left the trial because they could not tolerate it.
One caveat matters when reading these rates. They come from one specific trial, with one specific molecule, one specific escalation schedule, and one specific population. They are not "the rates for the class." Semaglutide's rates in STEP-1 and tirzepatide's in SURMOUNT-1 are different numbers, in different populations, over different durations.
The signs that call for a doctor
The GLP-1 side effects described so far, nausea included, are the frequent ones, and they are generally mild to moderate. Others do not belong in that category, and for those the only correct response is to see a medical professional:
- Severe, persistent abdominal pain, especially if it radiates to the back.
- Vomiting that makes it impossible to stay hydrated.
- Signs of dehydration.
- Jaundice (yellowing of the skin or eyes).
- Pain in the upper right quadrant of the abdomen.
- Recent-onset vision changes.
- Any symptom of an allergic reaction.
This article does not describe how to manage any of these, and that omission is deliberate. The instruction is a single one: consult a medical professional.
What the evidence does not settle
Why individual variability is so wide. Some people barely report symptoms at the top dose, and others cannot tolerate the starting one. There is no established predictor.
Whether constipation ever resolves. The trials report aggregate rates, not detailed time curves by symptom. The long-term course of constipation is characterized worse than that of nausea.
What happens in excluded populations. Prior digestive surgery, gastroparesis, inflammatory bowel disease: trials usually exclude them, so there are no data.
The TRIUMPH-1 rates are not published in a journal. They come from sponsor communication. Peer-reviewed publication may qualify them.
Frequently asked questions
Does nausea go away over time?
In the trials, gastrointestinal events cluster during escalation and decline in maintenance. That is the aggregate pattern; it does not predict the course for any one person.
Does constipation behave like nausea?
No. Nausea tends to soften with sustained exposure; constipation tends to persist, because it depends on slowed transit, which is a maintained effect.
Why do the rates change so much from one article to the next?
Because every figure belongs to a trial, a molecule, a dose, and a population. A rate quoted without those four items is not comparable to any other.
Which dose produces the fewest adverse effects?
Across every trial in the class the pattern is dose-dependent: less dose, fewer events. Which dose fits a given person is not a question a blog answers.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021;384:989–1002. DOI: 10.1056/NEJMoa2032183
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022;387:205–216. DOI: 10.1056/NEJMoa2206038
- Phase III retatrutide study demonstrates 30% weight loss (TRIUMPH-1, safety data). The Pharmaceutical Journal, May 21, 2026. pharmaceutical-journal.com
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism, 2018;27(4):740–756. DOI: 10.1016/j.cmet.2018.03.001
Written by the Bionic Editorial Team. Last reviewed: August 2026.
How we work: our editorial policy and source hierarchy.
These figures come from clinical research protocols conducted under medical supervision. They are not a usage recommendation, nor a protocol applicable outside that context.
This content is strictly educational and does not constitute medical advice, diagnosis or a therapeutic recommendation. The compounds mentioned are research products (Research Use Only) and are not approved by INVIMA, FDA, EMA or ANSM for therapeutic use in humans. Any health-related decision should be made with a licensed medical professional.